Nikhil Prasad Fact checked by:Thailand Medical News Team Jul 23, 2024 3 months, 3 weeks, 22 hours, 37 minutes ago
Pharma News: A New Dawn for Alzheimer's Treatment
In the relentless pursuit of breakthroughs in Alzheimer's disease treatment, Asceneuron, a Swiss biotechnology company, has made significant strides. The company recently announced the successful completion of a US$100 million Series C funding round, spearheaded by Novo Holdings. This financial boost is set to propel Asceneuron's innovative oral small molecule drug, ASN51, into Phase 2 clinical trials. This development marks a crucial milestone in the ongoing battle against Alzheimer's, offering new hope to millions affected by this debilitating disease.
Asceneuron secures 100 million dollars for new Alzheimer drug
The Promise of ASN51: A Paradigm Shift in Alzheimer's Treatment
Asceneuron's ASN51 stands out in the crowded field of Alzheimer's research due to its unique mode of action. Unlike existing treatments that primarily target amyloid beta proteins, ASN51 focuses on intracellular tau, a protein closely linked to the progression of Alzheimer's disease. This novel approach, according to Dr Naveed Siddiqi, M.D., Senior Partner for Venture Investments at Novo Holdings, offers the potential for a paradigm shift in Alzheimer's treatment. The drug's ability to inhibit the OGA enzyme has shown promise in preventing the aggregation of tau proteins, a key factor in the neurodegenerative process. Dr Siddiqi told
Pharma News reporters, “Alzheimer’s disease is undergoing a transformational moment. Millions are afflicted by this devastating disease and there are very few therapeutic options. Validated biomarkers are allowing for more focused and rapid drug development. Asceneuron's ASN51 has been identified as a promising Alzheimer drug.”
Funding and Strategic Support: A Strong Backing
The $100 million Series C funding round saw participation from a prestigious group of investors. Alongside Novo Holdings, new investors such as EQT Life Sciences Dementia Fund, OrbiMed, and SR One joined the round. They were accompanied by previous backers, including M Ventures, Sofinnova Partners, GSK Equity Investments, and Johnson & Johnson’s investment arm, JJDC. The inclusion of such high-caliber life sciences investors not only provides financial support but also validates the potential of Asceneuron's OGA inhibitor pipeline.
Leadership and Vision: A Committed Team
Under the leadership of CEO Barbara Angehrn Pavik, who joined Asceneuron in October 2023, the company is poised for significant advancements. Pavik, previously the Chief Business Officer at Vifor, expressed excitement about the progress of ASN51 into Phase 2 clinical development. Her vision aligns with the company's mission to expand treatment options for patients with Alzheimer's disease significantly.
The Competitive Edge: Oral Formulation and Convenience
One of the standout features of ASN51 is its oral formulation, which offers a sign
ificant advantage over existing treatments like Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla, both of which require intravenous infusion or injection. The convenience of a daily oral dose could enhance patient compliance and quality of life, making ASN51 a potentially more accessible and user-friendly option for Alzheimer's patients.
Broader Implications: Beyond Alzheimer's
While Alzheimer's is the primary focus, Asceneuron's research into OGA inhibitors has broader implications. Inhibiting the OGA enzyme has shown potential in preventing the aggregation of proteins linked to other neurodegenerative diseases, including Parkinson’s disease and amyotrophic lateral sclerosis (ALS). This broader applicability underscores the transformative potential of Asceneuron's research and development efforts.
Historical Context and Future Prospects
Asceneuron was founded in 2012 as a spinout from Merck KGaA’s Serono division. Initially supported by 6 million Swiss francs in seed funding, the company quickly gained traction, raising an additional 30 million Swiss francs in a Series A round by 2015. This early support laid the groundwork for Asceneuron's current successes and its ongoing efforts to tackle neurodegeneration.
In recent years, startups focused on neurological and psychiatric disorders have continued to attract significant investment. Companies like Cerevance and Therini Bio have secured substantial funding to develop innovative treatments for conditions such as Alzheimer's. These investments reflect a growing recognition of the urgent need for new and effective therapies in the field of neurodegeneration.
Asceneuron's Competitive Landscape
Asceneuron's journey is part of a broader trend in biotech where companies like Cerevance, MapLight Therapeutics, and Therini Bio are also making strides. Cerevance, for example, launched in 2016 with $36 million in backing from Takeda Pharmaceutical and recently attracted significant investment from Merck & Co. Similarly, MapLight Therapeutics secured $225 million in a Series C round led by Novo Holdings to advance its research into schizophrenia and Alzheimer's disease psychosis.
A Bright Future Ahead
Asceneuron's recent $100 million funding round is more than just a financial milestone; it represents a beacon of hope for millions of Alzheimer's patients and their families. With ASN51 poised to enter Phase 2 clinical trials, the potential for a new, more effective treatment for Alzheimer's is on the horizon. The support from leading life sciences investors and the innovative approach of targeting intracellular tau proteins position Asceneuron as a formidable player in the fight against neurodegenerative diseases.
As the field of neuroscience R&D continues to evolve, Asceneuron's advancements signal a promising future. The company's commitment to pushing the boundaries of Alzheimer's treatment, supported by substantial investment and strategic partnerships, underscores the critical importance of innovative research in overcoming one of the most challenging diseases of our time.
For the latest
Pharma News, keep on logging to Thailand Medical News.
Read Also:
https://www.thailandmedical.news/news/american-pharma-giant-pfizer-to-settle-more-than-10000-lawsuits-for-its-gastric-reflux-drug-zantac-that-causes-cancer
https://www.thailandmedical.news/news/blackrock-funds-moderna-us-750-million-dollars-to-develop-mrna-flu-vaccines-validating-that-a-flu-virus-is-likely-one-of-the-three-disease-x-pathogens
Share
Tweet
Share
